RIO Trial
@riotrial.bsky.social
Hello, RIO Trial is also now on Bluesky!
The RIO study is looking at whether a new type of treatment (bNAbs) can keep HIV viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
https://riotrial.org/
The RIO study is looking at whether a new type of treatment (bNAbs) can keep HIV viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
https://riotrial.org/
Pinned
RIO Trial
@riotrial.bsky.social
· Mar 11
RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Reposted by RIO Trial
Abstracts from the Spring 2025 @bhiva.bsky.social conference (open access):
onlinelibrary.wiley.com/toc/14681293...
#BHIVA25
onlinelibrary.wiley.com/toc/14681293...
#BHIVA25
BHIVA Spring Conference 2025, 23 April – 25 April 2025, Brighton, UK: HIV Medicine: Vol 26, No S2
Click on the title to browse this issue
onlinelibrary.wiley.com
April 22, 2025 at 8:01 PM
Abstracts from the Spring 2025 @bhiva.bsky.social conference (open access):
onlinelibrary.wiley.com/toc/14681293...
#BHIVA25
onlinelibrary.wiley.com/toc/14681293...
#BHIVA25
i-base.info/htb/50971
Want to find out more about RIO?
The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study.
Read more about it here ⬆️
Want to find out more about RIO?
The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study.
Read more about it here ⬆️
The RIO study: Q&A about controlling HIV with bNAbs | HTB | HIV i-Base
i-base.info
April 23, 2025 at 11:41 AM
i-base.info/htb/50971
Want to find out more about RIO?
The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study.
Read more about it here ⬆️
Want to find out more about RIO?
The brilliant @hiv-i-base.bsky.social team have published a non-technical Q&A on the recently reported results of the RIO study.
Read more about it here ⬆️
@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs
April 23, 2025 at 8:07 AM
@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs
Reposted by RIO Trial
Delighted to be able to present my PhD findings of bNAb in gut tissue, alongside the primary RIO trial findings at the Keystone HIV cure symposium in Durban!
#KeystoneSymposium #HIVcure2025
#KeystoneSymposium #HIVcure2025
Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa.
#KeystoneSymposium #HIVcure
#KeystoneSymposium #HIVcure
April 10, 2025 at 7:23 AM
Delighted to be able to present my PhD findings of bNAb in gut tissue, alongside the primary RIO trial findings at the Keystone HIV cure symposium in Durban!
#KeystoneSymposium #HIVcure2025
#KeystoneSymposium #HIVcure2025
People who receive bNAbs respond differently, some experience delayed rebound beyond 20 weeks after one dose, and some do not rebound at all. However some people still experienced early rebound despite being screened for predicted bNAb resistance.
#KeystoneSymposium #HIVcure2025
#KeystoneSymposium #HIVcure2025
April 10, 2025 at 7:09 AM
People who receive bNAbs respond differently, some experience delayed rebound beyond 20 weeks after one dose, and some do not rebound at all. However some people still experienced early rebound despite being screened for predicted bNAb resistance.
#KeystoneSymposium #HIVcure2025
#KeystoneSymposium #HIVcure2025
Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa.
#KeystoneSymposium #HIVcure
#KeystoneSymposium #HIVcure
April 10, 2025 at 6:58 AM
Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa.
#KeystoneSymposium #HIVcure
#KeystoneSymposium #HIVcure
Reposted by RIO Trial
La lueur d'espoir qu'il me fallait pour commencer la journée :)
Je ferai peut-être partie de la dernière génération à devoir vivre avec le VIH sur le long terme.
La recherche avance ✊💉🏥
Je ferai peut-être partie de la dernière génération à devoir vivre avec le VIH sur le long terme.
La recherche avance ✊💉🏥
Promising results from 2 HIV cure studies using antibodies.
In one 20% of participants stayed off treatment without viral rebound for two years!
Note: This seems far more likely to result in a workable cure for all (or many) than dangerous stem cell therapy.
#CROI2025
www.aidsmap.com/news/mar-202...
In one 20% of participants stayed off treatment without viral rebound for two years!
Note: This seems far more likely to result in a workable cure for all (or many) than dangerous stem cell therapy.
#CROI2025
www.aidsmap.com/news/mar-202...
Half the men in an HIV cure study stayed off treatment for nearly a year after a two-antibody shot
The day before the Conference on Retroviruses and Opportunistic Infections (CROI 2025) opened in San Francisco on Sunday, there was a community workshop on HIV cure science, at which Dr Michael Peluso...
www.aidsmap.com
March 14, 2025 at 8:41 AM
La lueur d'espoir qu'il me fallait pour commencer la journée :)
Je ferai peut-être partie de la dernière génération à devoir vivre avec le VIH sur le long terme.
La recherche avance ✊💉🏥
Je ferai peut-être partie de la dernière génération à devoir vivre avec le VIH sur le long terme.
La recherche avance ✊💉🏥
Reposted by RIO Trial
Promising results from 2 HIV cure studies using antibodies.
In one 20% of participants stayed off treatment without viral rebound for two years!
Note: This seems far more likely to result in a workable cure for all (or many) than dangerous stem cell therapy.
#CROI2025
www.aidsmap.com/news/mar-202...
In one 20% of participants stayed off treatment without viral rebound for two years!
Note: This seems far more likely to result in a workable cure for all (or many) than dangerous stem cell therapy.
#CROI2025
www.aidsmap.com/news/mar-202...
Half the men in an HIV cure study stayed off treatment for nearly a year after a two-antibody shot
The day before the Conference on Retroviruses and Opportunistic Infections (CROI 2025) opened in San Francisco on Sunday, there was a community workshop on HIV cure science, at which Dr Michael Peluso...
www.aidsmap.com
March 14, 2025 at 8:37 AM
Promising results from 2 HIV cure studies using antibodies.
In one 20% of participants stayed off treatment without viral rebound for two years!
Note: This seems far more likely to result in a workable cure for all (or many) than dangerous stem cell therapy.
#CROI2025
www.aidsmap.com/news/mar-202...
In one 20% of participants stayed off treatment without viral rebound for two years!
Note: This seems far more likely to result in a workable cure for all (or many) than dangerous stem cell therapy.
#CROI2025
www.aidsmap.com/news/mar-202...
Reposted by RIO Trial
As RIO and other groups have shown, bNAbs may be most promising as an immunotherapeutic intervention to enhance immun rasponsew, rather than as ART treatment. #CROI2025
March 12, 2025 at 7:58 PM
As RIO and other groups have shown, bNAbs may be most promising as an immunotherapeutic intervention to enhance immun rasponsew, rather than as ART treatment. #CROI2025
Reposted by RIO Trial
Exciting early riotrial.bsky.social results a#CROI202525:i-base.info/htb/50530
Ne#bNABsBs so far successful in keeping viral load undetectable in some participants of#HIVtreatmentnt.
Also the first time we’ve seen bNABs cause vaccine-like immune response.#RIOtriala#teropavimaba#zinlirvimabab
Ne#bNABsBs so far successful in keeping viral load undetectable in some participants of#HIVtreatmentnt.
Also the first time we’ve seen bNABs cause vaccine-like immune response.#RIOtriala#teropavimaba#zinlirvimabab
March 13, 2025 at 3:04 PM
Exciting early riotrial.bsky.social results a#CROI202525:i-base.info/htb/50530
Ne#bNABsBs so far successful in keeping viral load undetectable in some participants of#HIVtreatmentnt.
Also the first time we’ve seen bNABs cause vaccine-like immune response.#RIOtriala#teropavimaba#zinlirvimabab
Ne#bNABsBs so far successful in keeping viral load undetectable in some participants of#HIVtreatmentnt.
Also the first time we’ve seen bNABs cause vaccine-like immune response.#RIOtriala#teropavimaba#zinlirvimabab
RIO is an international collaboration bringing together researchers from Rockefeller, Imperial College London, University of Oxford, and clinical sites across UK and Europe.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
March 13, 2025 at 12:16 PM
RIO is an international collaboration bringing together researchers from Rockefeller, Imperial College London, University of Oxford, and clinical sites across UK and Europe.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
Reposted by RIO Trial
Our ICTU Statistician Louise-Rae Cherrill is at #CROI2025 for the presentation of exciting results of the ICTU-managed @riotrial.bsky.social with promising advances in #HIVTreatment driven by immune-based therapies www.imperial.ac.uk/news/261858/...
March 12, 2025 at 11:01 AM
Our ICTU Statistician Louise-Rae Cherrill is at #CROI2025 for the presentation of exciting results of the ICTU-managed @riotrial.bsky.social with promising advances in #HIVTreatment driven by immune-based therapies www.imperial.ac.uk/news/261858/...
www.youtube.com/watch?v=QnFb...
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
CROI 2025 Monday (March 10) Press Conference
YouTube video by IAS-USA
www.youtube.com
March 11, 2025 at 7:24 PM
www.youtube.com/watch?v=QnFb...
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
RIO chief investigator, Professor Sarah Fidler, was also invited to present at the #CROI2025 press conference, on 10th March 2025.
Time stamps of where you can watch about the RIO Trial:
Professor Fidler presents (3:05 – 6:22)
Press questions (16:04 – 20:10)
Yesterday at the #CROI2025 conference in San Francesco, we were delighted to report promising results of the primary outcome of our RIO Trial , which tested long-acting immune-based therapies for HIV.
March 11, 2025 at 7:21 PM
Yesterday at the #CROI2025 conference in San Francesco, we were delighted to report promising results of the primary outcome of our RIO Trial , which tested long-acting immune-based therapies for HIV.
Reposted by RIO Trial
New hope for #HIV treatment?
Research led by @imperialcollegeldn.bsky.social unveils promising trial results showing antibody therapies could control HIV without daily medication.
Read more 👇 imperial.ac.uk/news/261858/...
@imperialinfect.bsky.social
Research led by @imperialcollegeldn.bsky.social unveils promising trial results showing antibody therapies could control HIV without daily medication.
Read more 👇 imperial.ac.uk/news/261858/...
@imperialinfect.bsky.social
Immune response may be harnessed to control HIV, RIO study shows | Imperial News | Imperial College London
New antibody therapies could offer alternative to current treatments.
imperial.ac.uk
March 11, 2025 at 4:07 PM
New hope for #HIV treatment?
Research led by @imperialcollegeldn.bsky.social unveils promising trial results showing antibody therapies could control HIV without daily medication.
Read more 👇 imperial.ac.uk/news/261858/...
@imperialinfect.bsky.social
Research led by @imperialcollegeldn.bsky.social unveils promising trial results showing antibody therapies could control HIV without daily medication.
Read more 👇 imperial.ac.uk/news/261858/...
@imperialinfect.bsky.social
Reposted by RIO Trial
The @riotrial.bsky.social shows that immune-based therapy can sustain viral control in multiple HIV participants, allowing them to stop daily antiretroviral medication for over a year, providing an alternative to current treatments.
@imperialmed.bsky.social
Full article 👇
tinyurl.com/29rsb458
@imperialmed.bsky.social
Full article 👇
tinyurl.com/29rsb458
RIO Study: New antibody therapies could offer alternative to current treatments – NIHR Imperial Biomedical Research Centre
<p>Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies.</p>
imperialbrc.nihr.ac.uk
March 11, 2025 at 2:15 PM
The @riotrial.bsky.social shows that immune-based therapy can sustain viral control in multiple HIV participants, allowing them to stop daily antiretroviral medication for over a year, providing an alternative to current treatments.
@imperialmed.bsky.social
Full article 👇
tinyurl.com/29rsb458
@imperialmed.bsky.social
Full article 👇
tinyurl.com/29rsb458
Reposted by RIO Trial
BNAbs we're safe with no serious adverse events associated with study drug or ATI.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
March 10, 2025 at 6:48 PM
BNAbs we're safe with no serious adverse events associated with study drug or ATI.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
Reposted by RIO Trial
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
March 10, 2025 at 6:48 PM
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Reposted by RIO Trial
Early trial results unveiled by Imperial researchers show exciting advances in HIV treatment.
For the first time, immune-based treatments have managed to control the virus in patients for long periods, without the need for antiretrovirals.
Find out more 🔽
www.imperial.ac.uk/news/261858/...
For the first time, immune-based treatments have managed to control the virus in patients for long periods, without the need for antiretrovirals.
Find out more 🔽
www.imperial.ac.uk/news/261858/...
Immune response may be harnessed to control HIV, RIO study shows | Imperial News | Imperial College London
New antibody therapies could offer alternative to current treatments.
www.imperial.ac.uk
March 11, 2025 at 10:42 AM
Early trial results unveiled by Imperial researchers show exciting advances in HIV treatment.
For the first time, immune-based treatments have managed to control the virus in patients for long periods, without the need for antiretrovirals.
Find out more 🔽
www.imperial.ac.uk/news/261858/...
For the first time, immune-based treatments have managed to control the virus in patients for long periods, without the need for antiretrovirals.
Find out more 🔽
www.imperial.ac.uk/news/261858/...
RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
March 11, 2025 at 1:37 PM
RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Hi everyone! We're very excited about joining the Bluesky community! This video explains our trial design and was coordinated by the Leadership group members: Simon Collins, Sarah Fidler, John Frater, Ming Lee and Hanna Box.
#hiv #riotrial #bNAbs #CROI
#hiv #riotrial #bNAbs #CROI
The RIO Trial - using a new immune-based therapy to treat HIV
This video is about a new HIV study called RIO. It uses a new immune-based therapy to treat HIV. The study is open to people who started HIV treatment soon after…
vimeo.com
March 11, 2025 at 1:25 PM